August 20, 2014
The HPV-16/18 AS04-adjuvanted vaccine demonstrated efficacy and immunogenicity without any safety concerns, according to recent study results published in Human Vaccines and Immunotherapeutics.
The study was a follow-up of a double blind, randomized, placebo-controlled trial (HPV-001). Researchers assessed the efficacy of a bivalent HPV-16/18 vaccine (Cervarix, GlaxoSmithKline) in a subset of 437 women from the original study enrolled at five Brazilian centers. Participants were aged 15 to 25 years, and had previously been assigned vaccination or placebo. For the current study (HPV-023), researchers followed participants for more than 9 years, taking annual measurements of anti-HPV-16/18 antibodies.